logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
1H 2023
Beyond Air, Inc.
Topline data from the Phase 1 study of Nitric Oxide Injection (UNO)
Cancer
Early 2023
Armata Pharmaceuticals, Inc.
Topline data from Phase 2 MAD cohort evaluating AP-PA02
Cystic Fibrosis
1H 2023
Cyclacel Pharmaceuticals Inc.
Finale data on phase I/II 065-101 study of Fadraciclib
Advanced Solid Tumors and Lymphoma
1H 2023
Cyclacel Pharmaceuticals Inc.
Interim data from Phase I/II 140-101 study of oral CYC140
Advanced Solid Tumors And Lymphoma
2023
NANOBIOTIX
Initial data from Initial Phase 1b/2 data for NBTXR3
Non-small cell lung cancer (NSCLC)
Early 2023
Omeros Corp.
Initial efficacy data from phase 1 trial of OMS906
Paroxysmal Nocturnal Hemoglobinuria (PNH)
2023
Sera Prognostics, Inc.
Interim data from PRIME study evaluating safety and efficacy of a preterm birth (PTB) prevention strategy using PreTRM test
Preterm Labor and Preterm Birth
2023
Mirati Therapeutics, Inc.
Initial data from Phase 1/2 clinical trial evaluating NX-5948
MTAP-Deleted Solid Tumor
Early 2023
Ocugen, Inc.
Topline data from Phase 2/3 immuno-bridging and broadening clinical trial of COVAXIN
Covid 19
1H 2023
Third Harmonic Bio, Inc.
Data readout from Phase Ia clinical trial of THB001
Chronic Inducible Urticaria
Q1 2023
Zai Lab Limited
Top-line results from the Phase 3 pivotal LUNAR study of Tumor Treating Fields
Non-Small Cell Lung Cancer (NSCLC)
Q1 2023
Zai Lab Limited
Topline data from the registrational ADHERE trial of SC Efgartigimo
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Q1 2023
Zai Lab Limited
Topline data from the Phase 3 EMERGENT-3 trial of KarXT
Schizophrenia
1H 2023
Aldeyra Therapeutics, Inc.
Topline results from Phase II clinical trial of ADX-629
Chronic Cough
1H 2023
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III AEGEAN trial of Imfinzi and chemotherapy
Non-Small Cell Lung Cancer
1H 2023
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III EMERALD-2 trial of Imfinzi in combination with Bevacizumab
Hepatocellular Carcinoma
1H 2023
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III DUO-O trial of Lynparza and Imfinzi with or without Bevacizumab
Advanced ovarian cancer 1L
2023
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III trial of Roxadustat
Anaemia in lower risk MDS patients
2023
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III NIAGARA trial of Imfinzi in combination with Gemcitabine and Cisplatin
Muscle Invasive Bladder Cancer
2023
AstraZeneca PLC
AZN.L, AZN
Data readout from Phase III Nile trial of Imfinzi in combination with Chemotherapy and/or Tremelimumab
Unresectable Urothelial Cancer
1H 2023
BioXcel Therapeutics, Inc.
Topline results from part one of the phase III SERENITY-III trial
Agitated Bipolar and Schizophrenia patients.
1H 2023
BioXcel Therapeutics, Inc.
Top-line results from the Phase 1 trial for at home use BXCL501
Major Depressive Disorder
Early 2023
BioXcel Therapeutics, Inc.
Final data from SCNC cohort of Phase 2 trial for BXCL701 in combination with KEYTRUDA
Metastatic Castration-Resistant Prostate Cancer patients with Small Cell Neuroendocrine (SCNC) or Adenocarcinoma Phenotype.
Q1 2023
Cabaletta Bio, Inc.
1-month safety and persistence data for the combination cohort of Phase 1 Trial of DSG3-CAART
Mucosal Pemphigus Vulgaris
1H 2023
AstraZeneca PLC
AZN.L, AZN
Data Readout from Phase III TROPION-Lung01 trial of Dato-DXd
Non-small Cell Lung Cancer